Describe Neuromuscular Junction & Mechanism of Block in detail.

The Neuromuscular Junction

Skeletal muscle contracts when a nerve impulse releases acetylcholine (ACh) from the motor nerve terminal; ACh crosses the synaptic cleft and binds nicotinic ACh receptors on the muscle end-plate, depolarising it and triggering contraction. ACh is then rapidly broken down by acetylcholinesterase. Neuromuscular blocking drugs (muscle relaxants) act at this postsynaptic nicotinic receptor to produce skeletal muscle paralysis, facilitating tracheal intubation, controlled ventilation and surgical access.

At the neuromuscular junction, acetylcholine binds postsynaptic nicotinic receptors; muscle relaxants act here, either mimicking ACh (depolarising) or blocking it (non-depolarising).

Two Classes of Block

Relaxants are either depolarising or non-depolarising. A depolarising agent (suxamethonium) mimics ACh: it binds and depolarises the end-plate, but — not being broken down by acetylcholinesterase — it keeps the receptor occupied, causing a brief fasciculation then flaccid paralysis (a persistently depolarised, unresponsive membrane). A non-depolarising agent is a competitive antagonist that blocks ACh from the receptor without depolarising it.

Uses

Muscle relaxants are used to facilitate tracheal intubation, to provide surgical relaxation (e.g. Abdominal surgery), and to allow controlled ventilation. They provide no anaesthesia or analgesia — a paralysed patient must be adequately anaesthetised, or awareness results.

Clinical Consequences of the Two Mechanisms

The mechanistic difference between the two classes explains almost everything that matters clinically. Because a depolarising agent is an agonist that first activates the receptor before paralysing it, it produces the initial fasciculations and their sequelae (muscle pains, potassium release, rises in pressure), it cannot be reversed by an anticholinesterase (more acetylcholine would only add to the depolarisation), and on a nerve stimulator it produces a block without fade. Because a non-depolarising agent is a competitive antagonist, its block can be overcome by increasing acetylcholine (the basis of neostigmine reversal), it produces no fasciculations, and it shows the characteristic fade and post-tetanic facilitation that reveal an incompletely-recovered junction.

• Relaxants act at the postsynaptic nicotinic ACh receptor → skeletal muscle paralysis.
• Depolarising (suxamethonium): agonist → fasciculations then flaccid paralysis; not reversed by neostigmine; no fade.
• Non-depolarising: competitive antagonist → no fasciculations; reversed by neostigmine; fade on TOF.
• Used to aid intubation, provide surgical relaxation, allow controlled ventilation.
• They give NO anaesthesia/analgesia — a paralysed patient must be anaesthetised (awareness risk).